Hsbc Holdings PLC Catalyst Pharmaceuticals, Inc. Transaction History
Hsbc Holdings PLC
- $159 Billion
- Q1 2025
A detailed history of Hsbc Holdings PLC transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Hsbc Holdings PLC holds 34,963 shares of CPRX stock, worth $872,676. This represents 0.0% of its overall portfolio holdings.
Number of Shares
34,963
Previous 36,337
3.78%
Holding current value
$872,676
Previous $758,000
11.74%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding CPRX
# of Institutions
389Shares Held
99.3MCall Options Held
37KPut Options Held
20.5K-
Black Rock Inc. New York, NY18.7MShares$467 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.5MShares$212 Million0.0% of portfolio
-
State Street Corp Boston, MA5.53MShares$138 Million0.01% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.42MShares$85.4 Million2.1% of portfolio
-
Goldman Sachs Group Inc New York, NY3.14MShares$78.3 Million0.01% of portfolio
About CATALYST PHARMACEUTICALS, INC.
- Ticker CPRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 102,820,000
- Market Cap $2.57B
- Description
- Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...